Daily Cardiology Research Analysis
Analyzed 119 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies span translational, basic, and clinical science. A large-animal study uncovers a metabolic vulnerability explaining why pressure-overloaded hearts are uniquely susceptible to anthracycline cardiotoxicity and suggests preventive strategies. A Nature Communications study maps chamber-specific chromatin interactions in human cardiomyocytes to functionally interpret noncoding disease variants, while a meta-analysis of 18 RCTs shows intravascular imaging-guided PCI reduces mortality, MI, and stent thrombosis.
Research Themes
- Cardio-oncology: metabolic vulnerability under pressure overload heightens anthracycline cardiotoxicity
- Noncoding genetics: chamber-specific chromatin architecture enables variant-to-function in cardiomyocytes
- Precision interventional cardiology: intravascular imaging guidance improves PCI outcomes
Selected Articles
1. Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.
In a pig model, pre-existing LV pressure overload created a high-energy-demand state that rendered the heart uniquely vulnerable to even low-dose doxorubicin, leading to excess mortality, LV dysfunction, fibrosis, and impaired mitochondrial respiration. Modulating contractile energetics with mavacamten rescued cardiomyocyte viability under combined anthracycline and hypertrophic stress.
Impact: This study mechanistically links LV pressure overload to anthracycline cardiotoxicity, offering a testable paradigm for risk stratification and prevention in cardio-oncology. It identifies energetic demand as a targetable vulnerability.
Clinical Implications: Patients with hypertension or valvular disease undergoing anthracyclines may warrant intensified cardio-oncology assessment (blood pressure control, imaging/biomarkers), dose tailoring, and exploration of strategies that lower myocardial energy demand.
Key Findings
- LV pressure overload increased mortality and reduced LVEF when combined with low-risk-dose doxorubicin, while doxorubicin alone preserved function.
- Pressure overload induced compensatory metabolic remodeling (reduced phosphocreatine) and heightened susceptibility to mitochondrial respiratory impairment with anthracycline.
- Mavacamten reduced energetic demand and rescued cardiomyocyte viability under combined hypertrophic and doxorubicin stress.
Methodological Strengths
- Large-animal (porcine) model with multimodal in vivo imaging (CMR/MRS/PET-CT) and end-point proteomics/mitochondrial assays
- Rigorous factorial design isolating effects of pressure overload vs anthracycline and their interaction
Limitations
- Preclinical animal model; human generalizability requires clinical validation
- Single anthracycline agent/dose schedule; preventive pharmacologic strategies not tested clinically
Future Directions: Prospective clinical studies in hypertensive/valvular patients receiving anthracyclines to test intensified cardio-oncology pathways and energetics-modulating interventions (e.g., dose optimization, myosin modulation).
BACKGROUND AND AIMS: Hypertension and valvular heart disease, both associated with left ventricular (LV) pressure overload, increase the risk of anthracycline cardiotoxicity. While epidemiologically established, the underlying mechanisms remain unclear, precluding identification of therapeutic targets. METHODS: Two-month-old Yucatan pigs (males and females) underwent aortic banding to induce LV pressure overload or no operation. After 4 months, animals received a low-risk cumulative dose of doxorubicin (5 weekly 1 mg/kg intravenous injections) or vehicle, generating four groups: (i) healthy controls (no LV overload, no doxorubicin), (ii) Dox (doxorubicin, no LV overload), (iii) Banding (B: LV overload, no doxorubicin), and (iv) B + Dox (LV overload plus doxorubicin). Cardiac function, structure, and metabolism were assessed over 8 months by cardiac magnetic resonance, magnetic resonance spectroscopy, and hybrid positron emission tomography/computed tomography. At study end, proteomics and mitochondrial structure and function were analysed. Complementary in vivo and ex vivo studies examined the mechanistic role of energetic imbalance. RESULTS: LV overload increased LV mass (P < .0001) and ejection fraction (P = .0081), with compensatory metabolic changes (drop in phosphocreatine (P = .022)). Low-risk Dox alone altered myocardial metabolism (increased glucose uptake, P = .014) but preserved cardiac function. In pigs with pre-existing LV pressure overload, doxorubicin increased mortality (P < .0001 vs all other groups), reduced left ventricular ejection fraction (LVEF) (P < .0001), increased fibrosis, and impaired mitochondrial respiration (P = .032). In HL-1 cardiomyocytes, reducing energy demand with mavacamten rescued cell viability under combined doxorubicin and hypertrophic stress. CONCLUSIONS: LV pressure overload increases myocardial susceptibility to anthracycline cardiotoxicity by inducing a high-energy-demand state. Anthracycline treatment, even at a low-risk dose, disrupts compensatory mechanisms in the pressure-overloaded heart, rapidly leading to cardiac dysfunction and heart failure. Preventive strategies targeting this metabolic vulnerability are urgently needed for patients with extant LV pressure overload (e.g. hypertension or valvular heart disease) who are undergoing anthracycline therapy.
2. Chamber-specific chromatin architecture guides functional interpretation of disease-associated Cis-regulatory elements in human cardiomyocytes.
Human atrial and ventricular cardiomyocytes possess chamber-specific CRE–promoter architectures that modulate gene expression; functional epigenetic silencing validated causal links. At the KCNJ2 locus, CREs harboring QT-associated variants altered expression and repolarization, enabling variant-to-function mapping relevant to arrhythmia susceptibility.
Impact: Provides a chamber-resolved regulatory atlas in human cardiomyocytes and functionally links noncoding genetic risk to electrophysiological phenotypes, advancing precision cardiogenomics.
Clinical Implications: Facilitates interpretation of GWAS signals for atrial vs ventricular diseases, prioritizes target genes/loci for functional validation and potential therapeutic modulation (e.g., enhancer targeting).
Key Findings
- Chamber-specific CRE–promoter interactions exist in human atrial and ventricular cardiomyocytes and modulate transcription.
- Functional epigenetic silencing validates causality of selected CREs in regulating target genes.
- At the KCNJ2 locus, CREs with QT-duration risk variants modulate KCNJ2 expression, channel currents, and cardiomyocyte repolarization.
Methodological Strengths
- Integrated epigenomics with chromatin interaction profiling in human atrial, ventricular, and failing cardiomyocytes
- Functional validation via epigenetic silencing and electrophysiologic readouts at disease-relevant loci
Limitations
- Tissue access and sample diversity may be limited; chamber maps derived from selected human samples
- Functional validation focused on exemplar loci; comprehensive causal testing across all CREs is pending
Future Directions: Expand to diverse ancestries and disease states, systematically perturb CREs across loci, and integrate with single-cell multi-omics to refine therapeutic target selection.
Cis-regulatory elements (CREs) are noncoding DNA regions regulating cell-type-specific gene expression programs by interacting with distal gene promoters. Here, we aim to decode the function and spatial organization of CRE-promoter interactions in human cardiomyocytes. We analyzed the epigenome and chromatin interactions of human male atrial, ventricular, and failing cardiomyocytes. Atrial and ventricular cardiomyocytes harbored chamber-specific CRE-promoter interactions modulating gene expression as confirmed by functional epigenetic silencing. These CRE-promoter interactions explain the distinct contribution of non-coding genetic variants to atrial and ventricular diseases, such as dilated cardiomyopathy and arrhythmias. We dissected the prototypic KCNJ2 locus, encoding a potassium channel associated with ventricular arrhythmia susceptibility. Functional epigenetic silencing confirmed that CREs, harboring QT-duration-associated genetic risk factors, modulate KCNJ2 gene expression levels, alter KCNJ2-dependent channel currents, and affect cardiomyocyte repolarization. The presented human CM-specific chromatin interaction analysis provides key insights into regulatory mechanisms and aids in interpreting genetic risk factors.
3. Contemporary evidence for intravascular imaging-guided percutaneous coronary intervention: a systematic review and meta-analysis of 21 812 patients from 18 randomized controlled trials.
Across 18 RCTs (n=21,812), intravascular imaging-guided PCI reduced target-vessel failure, cardiac death, all-cause mortality, MI, and definite stent thrombosis versus angiography/FFR-guided PCI. Absolute event rates were low, yielding modest absolute risk reductions.
Impact: Aggregated randomized evidence demonstrates outcome benefits beyond procedural metrics, strengthening the case for routine imaging guidance in PCI.
Clinical Implications: Hospitals should consider default IVUS/OCT guidance, especially for complex lesions, balancing resource allocation with demonstrated reductions in death, MI, and stent thrombosis.
Key Findings
- Imaging-guided PCI lowered TVF (RR 0.66), cardiac death (RR 0.56), all-cause mortality (RR 0.77), MI (RR 0.84), and definite stent thrombosis (RR 0.41).
- No significant differences in repeat revascularization or contrast-induced nephropathy.
- Benefits occurred despite low absolute event rates, implying modest absolute risk reduction.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with systematic multi-database search
- Clinically meaningful endpoints including mortality and stent thrombosis with random-effects modeling
Limitations
- Heterogeneity in imaging protocols, lesion complexity, and operator experience across trials
- Low absolute event rates limit absolute risk reduction magnitude and cost-effectiveness generalizations
Future Directions: Health-economic analyses and implementation studies to optimize imaging use in different patient subsets and healthcare systems.
BACKGROUND: Coronary artery disease (CAD) remains a leading cause of global morbidity and mortality. This meta-analysis aimed to compare clinical outcomes of intravascular imaging-guided percutaneous coronary intervention (PCI) versus angiography - or fractional flow reserve (FFR)-guided PCI. METHODS: We systematically searched six databases through October 2024 for randomized controlled trials (RCTs) comparing intravascular ultrasound (IVUS)-guided or optical coherence tomography (OCT)-guided PCI versus angiography-guided or FFR-guided PCI. Primary outcomes included target-vessel failure (TVF), myocardial infarction (MI), mortality, stent thrombosis, repeat revascularization, and contrast-induced nephropathy. Risk ratios (RRs) were pooled using a random-effects model. RESULTS: Eighteen RCTs including 21 812 patients (11 215 imaging-guided; 10 597 angiography/FFR-guided) were analyzed. Imaging-guided PCI was associated with lower risks of TVF (RR: 0.66; 95% CI: 0.58-0.74), cardiac death (RR: 0.56; 95% CI: 0.44-0.71), all-cause mortality (RR: 0.77; 95% CI: 0.64-0.93), MI (RR: 0.84; 95% CI: 0.71-0.99), and definite stent thrombosis (RR: 0.41; 95% CI: 0.27-0.62). No significant differences were observed in repeat revascularization (RR: 0.99; 95% CI: 0.75-1.31) or contrast-induced nephropathy (RR: 1.08; 95% CI: 0.64-1.83). Although relative risk reductions were significant, absolute event rates were low, resulting in modest absolute risk reductions. CONCLUSION: Intravascular imaging-guided PCI significantly improves key clinical outcomes, including mortality, MI, and stent thrombosis, compared with angiography-guided or FFR-guided PCI. These findings support broader implementation of IVUS and OCT in contemporary PCI, especially in patients with complex coronary disease.